Although most mechanistic studies are performed in mice, studies have shown that targeting TIM-1 enhances type I interferon (IFN-I) responses, promotes B cells antigen presentation and activation, and enhances T cell anti-tumour responses, thus inhibiting tumour growth [101]. This evidence concerns the gene HAVCR1 and neoplasm.